NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading XNCR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The current thesis state is cautious due to recent financial struggles and elevated risks, despite some positive sector momentum.
The market appears to have low expectations for XNCR, with a notable expectations gap. Valuation suggests that the stock is trading at a premium compared to peers, indicating that investors may be cautious about its future performance.
Fundamentals are likely to remain weak in the near term, as management has struggled to reduce losses and improve cash flow. Recent financial results show significant declines in revenue, which may continue to affect investor sentiment.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX. If these companies continue to perform well, it could provide a tailwind for XNCR, but any negative guidance from them could lead to further challenges.
Over the next 1 to 3 years, XNCR's performance will depend on its ability to stabilize its financials and the broader healthcare sector's momentum. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report showed a significant miss. This performance is below what was expected and raises concerns about future growth.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: An updated financial outlook will clarify the impact of the earnings miss on cash flow.
Confirms:Management will share a new cash flow outlook after the earnings miss on August 5, 2026.
Disproves:No change in cash flow guidance despite the earnings miss.
Why it matters: Progress in this study is key for Xencor's rheumatoid arthritis treatments.
Confirms:Positive update on progress from the Phase 1b study of Plamotamab in 2H26.
Disproves:No update or negative results from the Phase 1b study.
Why it matters: Better cash flow is key for funding research. A good update could help investors feel better.
Confirms:Cash flow from operations improves from -$67.63M in 2026-Q1.
Disproves:Cash flow from operations worsens or remains negative.
Why it matters: Higher revenue growth shows success in making more money. This is very important.
Confirms:Q2 revenue grows year over year by more than 5%.
Disproves:Q2 revenue growth is less than 5% year over year.
Why it matters: Worsening cash flow indicates deeper financial issues. It shows the company is struggling to manage its costs.
Confirms:Cash flow from operations worsens beyond -$67.6M in Q2.
Disproves:Cash flow from operations improves to less negative than -$67.6M in Q2.
Why it matters: Improving cash flow is crucial for the company's financial health and future growth.
Confirms:Cash flow from operations turns positive in Q2.
Disproves:Cash flow from operations remains negative in Q2.
Why it matters: A clear plan from management could indicate a turnaround strategy. Investors want to see action on reducing losses.
Confirms:Management has a clear plan. They want to lower net losses in the next earnings call.
Disproves:No clear plan is presented to address net losses in the next earnings call.
Why it matters: A decrease in net losses shows progress in managing costs, which is a key priority.
Confirms:Q2 net losses decrease year over year by more than 10%.
Disproves:Q2 net losses increase year over year or stay the same.
Why it matters: Starting this study is key for Xencor's TL1A work on autoimmune diseases.
Confirms:The start of the XmAb412 first-in-human study will be announced in 3Q26.
Disproves:Delay in starting the study beyond 3Q26.
Why it matters: This update will show how XmAb942 may help treat ulcerative colitis.
Confirms:An update on the Phase 2b XENITH-UC study is expected by the end of 2026.
Disproves:There are no updates or bad results from the interim analysis.
Why it matters: This data will help start an important study in 2027.
Confirms:Results from the Phase 1 study will be shared at a medical conference in 2H26.
Disproves:No data presented or results show no efficacy in the cohort.
